Arrowstreet Capital
VRDN icon

Arrowstreet Capital’s Viridian Therapeutics VRDN Stock Holding History

Arrowstreet Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.4M Buy
1,112,413
+1,089,134
+4,679% +$17.5M 0.01% 851
2026
Q1 		$455K Sell
23,279
-317,979
-93% -$9.44M ﹤0.01% 1685
2025
Q4 		$10.6M Buy
+341,258
New +$9.36M 0.01% 906

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital's VRDN Position: Q2 2026 in Review

Arrowstreet Capital increased its Viridian Therapeutics (VRDN) stake by 4,679% in Q2 2026, buying an estimated $17.5M and bringing the position to 1,112,413 shares worth $20.4M. The position accounts for 0.01% of the portfolio, ranked #851.

Arrowstreet Capital first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Arrowstreet Capital held 1,112,413 shares of Viridian Therapeutics worth $20.4M as of Q2 2026.
  • Arrowstreet Capital bought 1,089,134 Viridian Therapeutics shares in Q2 2026, an estimated $17.5M.
  • Viridian Therapeutics made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #851 holding.
  • Arrowstreet Capital first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.